Drug intelligence / Profile preview

IDX184 + peginterferon alfa-2a + ribavirin

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral, Subcutaneous

Overview

IDX184 + peginterferon alfa-2a + ribavirin is an investigational oral combination regimen intended for the treatment of chronic hepatitis C virus (HCV) infection. IDX184 is a liver-targeted prodrug of 2'-methylguanosine monophosphate, acting as a nucleotide analog inhibitor of HCV NS5B RNA-dependent RNA polymerase. Peginterferon alfa-2a is a pegylated form of interferon-alfa with immunomodulatory and antiviral properties, while ribavirin is a synthetic nucleoside analog with broad-spectrum antiviral activity. This combination aims to increase sustained virologic response rates by combining direct-acting antiviral (IDX184) with standard of care interferon-based backbone.

Other names: pegylated interferon alfa-2a + ribavirin + IDX184

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on IDX184 + peginterferon alfa-2a + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDX184 + peginterferon alfa-2a + ribavirin.

Explore the full profile